Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari speaks with Proactive's Stephen Gunnion about the company’s listing on Nasdaq, marking a key milestone for the biotechnology firm. Medicus raised $4 million through the IPO to fund its ongoing phase 2 proof-of-concept trial for a promising noninvasive treatment for basal cell carcinoma, the most common form of skin cancer. The $15 billion market for skin cancer treatments reflects a significant unmet need, and Medicus Pharma aims to address this with a novel combination therapy developed in collaboration with Carnegie Mellon University and the University of Pittsburgh. Bokhari emphasized that the treatment could offer a less costly, non-surgical alternative with strong aesthetic benefits. He also shared that since the company’s Toronto Stock Exchange listing last year, it has raised over $20 million, underscoring investor interest in innovative, disruptive cancer therapies. As Medicus Pharma seeks alignment with the FDA, Bokhari expressed hopes to expedite the phase 2 trial and potentially convert it to a pivotal trial early in 2025, positioning the company to take the next big step in its development journey. "We believe we have a novel treatment that can cut costs and eliminate the need for surgical intervention," Bokhari stated. The new funds will bolster Medicus Pharma’s progress, with patient recruitment already underway. Stay tuned to Proactive's YouTube channel for more updates from Medicus Pharma Ltd. Don’t forget to like this video, subscribe to our channel, and turn on notifications for future content. #MedicusPharma, #NasdaqIPO, #BiotechInvesting, #CancerResearch, #BasalCellCarcinoma, #RazaBokhari, #NoninvasiveTreatment, #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews